Factors associated with distant recurrence (DR) risk in patients (pts) with HR+/HER2-early breast cancer (EBC): a machine learning (ML) model-based analysis using real-world (RW) data

被引：0
|
作者：
Sparano, J. A. [1 ]
Lustberg, M. B. [2 ]
de Nonneville, A. [3 ]
Bachelot, T. [4 ]
Santa-Maria, C. A. [5 ]
Blyuss, O. [6 ]
Fasching, P. A. [7 ]
Brezden-Masley, C. [8 ]
Park, Y. H. [9 ]
Akdere, M. [10 ]
Ye, F. [11 ]
Pattipaka, T. [10 ,12 ]
Manneni, V. R.
Kurz, C. [13 ]
Castro, P. Dominguez [14 ]
Howard, F. M.
机构：
[1] Tisch Canc Inst, T Canc Inst, New York, NY 10029 USA
[2] Yale Univ, Sch Med, Sch Med, New Haven, CT USA
[3] Aix Marseille Univ, Inst Paoli Calmettes, CRCM, CNRS,INSERM,CRCM, Marseille, France
[4] Ctr Leon Berard, Dept Med Oncol, Lyon, France
[5] Sidney Kimmel Comprehens Canc Ctr Johns Hopkins, Breast & Gynecol Malignancies Grp, Baltimore, MD USA
[6] Queen Mary Univ London, Wolfson Inst Populat Hlth, Ctr Prevent Detect & Diag, London, England
[7] Friedrich Alexander Univ Erlangen Nuremberg, Univ Hosp Erlangen Comprehens Canc Ctr Erlangen EM, Erlangen, Germany
[8] Univ Toronto, Mt Sinai Hosp, Fac Med, Div Med Oncol & Hematol, Toronto, ON, Canada
[9] Sungkyunkwan Univ, Sch Med, Div Hematol Oncol, Div Hematol Oncol,Sch Med, Seoul, South Korea
[10] Novartis Pharm AG, Basel, Switzerland
[11] Novartis Pharmaceut, E Hanover, NJ USA
[12] Novartis Healthcare Pvt Ltd, Hyderabad, Telangana, India
[13] Novartis Pharma GmbH, Munich, Germany
[14] Novartis Ireland, Dublin, Ireland
来源：
BREAST | 2025年 / 80卷
关键词：
D O I：
10.1016/j.breast.2025.104097
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P258
引用
收藏
页数：2
相关论文
共 36 条
  • [21] APOBEC signature, clinical characteristics, and outcome in hormone receptor-positive (HR+) HER2-negative (HER2-) breast cancer (BC) patients (pts) in real-world data (RWD)
    Chumsri, Saranya
    Raskina, Kira
    Sammons, Sarah
    Alder, Laura
    Danziger, Natalie
    Schrock, Alexa B.
    McGregor, Kim
    Sokol, Ethan
    CANCER RESEARCH, 2022, 82 (04)
  • [22] Identifying genetic factors of response and resistance to CDK4/6 inhibitors in metastatic HR+/HER2-breast cancer using real-world data.
    Agrawal, Smita
    Singh, Neeraj
    Narayanan, Babu
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [23] The Endocrine Treatment Landscape for Patients with HR+ HER2-Early-stage Breast Cancer in Germany Before the Introduction of CDK4/6 Inhibitor Therapy - A Real-World Analysis
    Nabieva, Naiba
    Altmann, Falk
    Apel, Klaus
    Baerens, Dirk-Toralf
    Beha, Michaela
    Belau, Antje
    Busch, Steffi
    Guth, Dagmar
    Heinrich, Georg
    Kreiss-Sender, Janine
    Markmann, Susanne
    Olbermann, Andreas
    Oskay-Oezcelik, Guelten
    Schuback, Beatrix
    Steinfeld-Birg, Dieter
    Quiering, Claudia
    Kiss, Ferenc
    Kreuzeder, Julia
    Nuti, Paolo
    Schilling, Joerg
    GEBURTSHILFE UND FRAUENHEILKUNDE, 2023, 83 (09) : 1127 - 1137
  • [24] Real-world (Rw) outcomes in patients (pts) with hormone receptor-positive and human epidermal growth factor receptor-2 negative (HR+/HER2-) metastatic breast cancer (mBC) treated with chemotherapy (CT) in France and Germany
    Campone, M.
    Frenel, J-S.
    Kiver, V. I. I.
    Woeckel, A.
    Kerscher, A. G.
    Krebs, M.
    Leal, C. S.
    Saglimbene, V. M.
    Trankov, N.
    Sadetsky, N.
    Sjekloca, N.
    Libert, O.
    Kaushik, A. G.
    Bocquet, F.
    ANNALS OF ONCOLOGY, 2024, 35 : S375 - S376
  • [25] Machine learning and natural language processing (NLP) approach to predict early progression to first-line treatment in real-world hormone receptor-positive (HR+)/HER2-negative advanced breast cancer patients
    Ribelles, Nuria
    Jerez, Jose M.
    Rodriguez-Brazzarola, Pablo
    Jimenez, Begona
    Diaz-Redondo, Tamara
    Mesa, Hector
    Marquez, Antonia
    Sanchez-Munoz, Alfonso
    Pajares, Bella
    Carabantes, Francisco
    Bermejo, Maria J.
    Villar, Ester
    Dominguez-Recio, Maria E.
    Saez, Enrique
    Galvez, Laura
    Godoy, Ana
    Franco, Leo
    Ruiz-Medina, Sofia
    Lopez, Irene
    Alba, Emilio
    EUROPEAN JOURNAL OF CANCER, 2021, 144 : 224 - 231
  • [26] Impact of comorbidities on real-world (rw) clinical outcomes of patients (pts) with hormone receptor-positive/human epidermal growth factor 2-negative (HR+/HER2-) advanced breast cancer (ABC) treated with palbociclib and enrolled in POLARIS
    Tripathy, D.
    Blum, J. L.
    Karuturi, M. S.
    McCune, S.
    Kurian, S.
    Moezi, M. M.
    Anderson, D. M.
    Wang, Y.
    Montelongo, M. Z.
    Zhang, Z.
    Gauthier, E.
    Rocque, G.
    ANNALS OF ONCOLOGY, 2023, 34 : S332 - S332
  • [27] Real-world treatment patterns among advanced HR+/ HER2-breast cancer patients in the post-CDK4/6 inhibitor era: An analysis of administrative claims data.
    Boyle, Tirza Areli Calderon
    Shukla, Soham
    Happ, Lindsey Powers
    Zheng, Shan
    Gorsh, Boris
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [28] Real-world clinical profile, treatment patterns and patient-reported outcomes in a subset of HR+/HER2-advanced breast cancer patients with poor prognostic factors: data from an international study
    Davie, A.
    Carter, G. Cuyun
    Rider, A.
    Bailey, A.
    Lewis, K.
    Price, G.
    Ostojic, H.
    Ringeisen, F.
    Pivot, X.
    ESMO OPEN, 2021, 6 (04)
  • [29] Five-year results of the prospective Phase III WSG PlanB trial confirm prognostic impact of 21-Gene Recurrence Score in high-risk HR+/HER2-early breast cancer (EBC) patients with 1-3 involved lymph nodes
    Gluz, O.
    Nitz, U.
    Christgen, M.
    Kates, R.
    Clemens, M.
    Nuding, B.
    Shak, S.
    Wuerstlein, R.
    Kreipe, H.
    Harbeck, N.
    BREAST, 2017, 32 : S93 - S93
  • [30] Real-world outcomes with adjuvant nonsteroidal aromatase inhibitors (NSAIs) vs tamoxifen (TAM) in patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) early breast cancer (EBC): A US database analysis.
    Graff, Stephanie L.
    Tolaney, Sara M.
    Hart, Lowell L.
    Razavi, Pedram
    Fasching, Peter A.
    Janni, Wolfgang
    Schwartzberg, Lee S.
    Lanoue, Brad
    Salas, Tonatiuh Romero
    Khakwani, Aamir
    McDermott, Courtney
    Pathak, Purnima
    O'Shaughnessy, Joyce
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
1234